These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8491812)

  • 1. Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography.
    Cashaw JL
    J Chromatogr; 1993 Apr; 613(2):267-73. PubMed ID: 8491812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans.
    Matsubara K; Fukushima S; Akane A; Kobayashi S; Shiono H
    J Pharmacol Exp Ther; 1992 Mar; 260(3):974-8. PubMed ID: 1545408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
    Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
    Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection.
    Sagar KA; Smyth MR
    Analyst; 2000 Mar; 125(3):439-45. PubMed ID: 10829343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
    LeWitt PA
    Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
    Cedarbaum JM; Kutt H; McDowell FH
    Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for determination of subpicomole concentrations of tetrahydropapaveroline in rat brain by high-performance liquid chromatography with electrochemical detection.
    Cashaw JL; Geraghty CA; McLaughlin BR; Davis VE
    Anal Biochem; 1987 Apr; 162(1):274-82. PubMed ID: 3605593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-duration action of levodopa may be due to a postsynaptic effect.
    Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
    Brusa L; Bassi A; Lunardi G; Fedele E; Peppe A; Stefani A; Pasqualetti P; Stanzione P; Pierantozzi M
    Eur J Neurol; 2004 Sep; 11(9):593-606. PubMed ID: 15379738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Method for the identification of tetrahydropapaveroline using the Pictet-Spengler condensation reaction and high-performance liquid chromatography.
    Geraghty CA; Cashaw JL
    J Chromatogr; 1989 Apr; 489(2):399-403. PubMed ID: 2753963
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
    Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E
    Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
    Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
    Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.